Bradford BCA peptide assay: common measurement errors

Accurate quantification of peptide concentration is foundational to reproducible laboratory research. Two colorimetric assays dominate research workflows: the Bradford assay, based on Coomassie dye binding to protein, and the BCA (bicinchoninic acid) assay, which detects Cu²⁺ reduction by peptide backbones. Both are rapid, cost-effective and suited to high-throughput sample analysis. However, each method carries known limitations that, when unrecognised, can introduce substantial error into downstream experiments.

The Bradford BCA peptide assay framework offers apparent simplicity: generate a standard curve using protein or peptide standards of known concentration, measure sample absorbance, and interpolate concentration from the curve. In practice, peptide composition, buffer chemistry, and assay conditions interact in ways that compromise linearity, precision and accuracy. Understanding these pitfalls is essential before deploying either method in critical research workflows.

The Bradford assay relies on non-covalent binding between Coomassie dye and positively charged amino acid residues (lysine, arginine, histidine). This mechanism immediately introduces a peptide-composition dependence absent from mass-balance methods. Peptides rich in basic residues will appear to have higher concentration than their true molar value; peptides deficient in these residues may appear underestimated.

A second limitation emerges from dye-binding kinetics. The reaction is not instantaneous and is sensitive to buffer ionic strength, pH, and temperature. In many published protocols, incubation time is fixed at 5 minutes; shorter incubation periods in some workflows yield incomplete colour development, whilst extended periods can show drift. Detergent-containing buffers (common in peptide solubilisation) are known to suppress colour development, yielding apparent concentration values substantially lower than the true concentration.

Turbidity—a common consequence of peptide aggregation during storage or reconstitution—confounds Bradford measurements. Peptide aggregates scatter light, increasing background absorbance and skewing apparent concentration upward. Centrifugation before measurement is often necessary but not always employed, introducing systematic error across sample batches.

The BCA assay measures peptide concentration indirectly via Cu²⁺ reduction in alkaline conditions. The reaction is robust and less dependent on amino acid composition than Bradford, making it suitable for a broader range of peptide types. However, the assay is exquisitely sensitive to metal ion contamination. Iron, copper, molybdenum and other transition metals pre-present in buffers, water or glassware can participate in the Cu²⁺ reduction reaction independently of peptide, inflating apparent concentration.

Storage vessel composition matters. Peptide solutions stored in standard borosilicate glassware can leach trace metals over weeks or months. Polypropylene tubes are preferable for long-term storage of samples intended for BCA quantification. Similarly, metal-binding chelators (EDTA, NTA) in the solubilisation buffer will suppress colour development if present at sufficient concentration, requiring either buffer exchange or use of an alternative assay.

Temperature control during the BCA colour development step is often overlooked. The reaction rate accelerates sharply with temperature; a 5 °C difference between standard curve and sample measurement can introduce 3–5% systematic error. Many laboratories run assays at ambient temperature without controlling for diurnal variation or seasonal drift in laboratory temperature.

Both Bradford and BCA assays assume linearity of the absorbance-versus-concentration relationship across the measurement range. In practice, this assumption fails at both extremes. At very low peptide concentrations (< 0.1 mg/mL), background absorbance dominates and precision deteriorates sharply. At high concentrations (> 2 mg/mL for Bradford, > 2.5 mg/mL for BCA), assay reagent becomes limiting, and the relationship becomes non-linear or plateaus.

A frequent workflow error is to prepare standard curves from commercial protein standards (bovine serum albumin, immunoglobulin) rather than the peptide of interest. Whilst this is computationally convenient, it conflates concentration determination with calibration uncertainty. The absorption-versus-concentration relationship for a 66 kDa protein differs from that of a 2 kDa peptide due to differences in amino acid distribution and secondary structure. Published research shows systematic overestimation of small peptide concentration (10–30% bias) when BSA standards are substituted.

R² values for standard curves are reported as quality metrics but provide false reassurance. A curve can show R² > 0.98 and still harbour substantial bias if only two to three standard concentrations are used, if outliers go undetected, or if the absorbance range is chosen to coincide only with the linear regime. Minimum six-point standard curves, spanning the full anticipated sample range, are advised.

Peptide samples are frequently supplied in non-aqueous or mixed solvent systems. Acetonitrile, DMSO, methanol and acetic acid solutions are common for lipophilic or poorly water-soluble peptides. These solvents interfere with both Bradford and BCA assays in concentration-dependent fashion. If acetonitrile concentration exceeds 10% (v/v), Bradford colour development is suppressed. Organic solvent-containing samples require buffer exchange or dilution in aqueous solvent prior to assay.

Peptide oxidation during storage or handling oxidises methionine and cysteine residues, altering the effective amino acid composition and thus the assay response. Oxidised peptide samples give lower apparent Bradford readings but may give paradoxically higher BCA readings due to formation of disulphide bonds and altered Cu²⁺ reactivity. Storage under inert atmosphere and use of antioxidant buffers (ascorbate, DTT) reduce this confound.

Salt concentration in the peptide solution merits attention. Sodium chloride at concentrations above 500 mM suppresses Bradford colour development through ionic competition. Phosphate buffers above 100 mM phosphate equivalents suppress BCA colour development. Many reconstitution protocols include buffering salts at problematic concentrations; overnight dialysis against assay buffer prior to measurement is prudent.

Industry best practice for high-confidence research workflows employs orthogonal quantification methods. Peptide concentration determination by UV-visible absorbance at 280 nm (measuring aromatic amino acid absorption) or 214 nm (peptide bond absorption) provides a complementary, composition-independent check. Mass spectrometry-based quantification using deuterated standards or amino acid analysis (HPLC or GC-MS post-hydrolysis) offer gold-standard accuracy but require specialist equipment and training.

When Bradford or BCA assays are the primary quantification method, reporting the result as a range (mean ± 95% confidence interval) rather than a point estimate acknowledges inherent uncertainty. This practice is aligned with UK MHRA and ISO 17043 guidance for reference material characterisation. A 10–15% uncertainty band is realistic for a single Bradford or BCA assay run; multiple independent measurements reduce this substantially.

Uncertainty propagates into downstream applications. If a peptide concentration is used to prepare a working solution for a receptor-binding assay or a cell-line assay, the uncertainty in the initial concentration measurement directly affects the apparent concentration-response relationship. A systematic 20% overestimation of peptide concentration will compress all subsequent concentration-response data by a factor of 1.2, potentially misrepresenting receptor pharmacology in published literature.

When deploying Bradford or BCA assays, record the following metadata with every measurement: buffer composition and pH, temperature during colour development, incubation time, absorbance wavelength and bandwidth, instrument model and calibration date, and visual inspection notes (turbidity, colour uniformity). This metadata enables post-hoc error detection and supports audit compliance.

Use peptide-matched or amino-acid-matched standards where feasible. If peptide-specific standards are unavailable, prepare standards from reconstituted peptide samples of known mass (by suppliers' mass spectrometry or NMR characterisation) rather than relying on commercial protein standards.

For high-precision research workflows, bracket sample measurements with standard curve replicates to detect instrumental drift. If absorbance of the lowest-concentration standard drifts by more than 5% between the start and end of a batch run, repeat the entire assay rather than risk systematic error.

Segregate peptides by solubility and composition. Hydrophobic peptides and cationic peptides show more pronounced assay-to-assay variability; allocate additional QC resources to these cohorts. For novel peptides of unknown composition, perform a small exploratory Bradford and BCA comparison before committing to a single assay method.